Neurocrine Biosciences Inc at Cowen Health Care Conference Transcript
Good morning, and welcome once again to Cowen and Company's 39th Annual Health Care Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen and Company, and it's my pleasure to have a fireside chat with our next company, Neurocrine. We're really happy to have with us today Kevin Gorman, CEO, and Matt Abernethy, CFO. We'll do about 30 minutes in this room and then there is no breakout following.
Questions & Answers
Kevin, maybe we'll start with you. Before we jump into this morning's data, could you give us a brief state-of-the-company overview? Where is Neurocrine in its long history and what you think needs to happen to drive outperformance over the next year or 2?
Sure, Phil. To start out, thank you very much for the invitation, and thank
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
